With Bioendo assistance, the China’s first GMP certified vaccine product approved use by the EU and launched in the EU market

At the end of 2019, the new crown epidemic was fierce. In December 2020, the inactivated new crown virus vaccine developed and produced by a well-known biopharmaceutical company was 86% effective against virus infection, and the neutralizing antibody conversion rate was 99%, which can be 100% preventive. severe and severe cases of COVID-19. The vaccine received emergency use authorization in a country in September to protect medical staff fighting on the front lines of the epidemic. A national drug approval and regulatory agency officially issued the EU GMP certificate for the new crown inactivated vaccine to the biopharmaceutical company. This is the first vaccine product approved for use in the EU and GMP certified in China’s history, taking a new step for China’s new crown vaccine to become a global public product. In order to truly reflect the effect of dry heat sterilization and depyrogenation of the vial vaccine production line, our company uses a unique production process to customize the 2ml, 3ml and other specifications of the same bottle type of vials used in the production of the biopharmaceutical company. High temperature resistant bacteria Endotoxin indicator (dry heat sterilized endotoxin indicator ECV), which solves the production requirements of vaccine products. Our company has done our part in the process of national new crown vaccine research and development, production, quality control, and endotoxin detection.